Letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD) discussing the ACMD work programme for 2025.
Advisory Council On The Misuse Of Drugs
- Guidance: Balai Directive: approved premises
- Research: Bird flu (avian influenza): findings in non-avian wildlife
- Bird flu (avian influenza): latest situation in England
- Form: Live animals (not pet dogs, cats, ferrets): import licence application
- Transparency data: Small boat activity in the English Channel
- Anniversary Statement: Cessna 208B, G-CPSS
- Unclaimed estates list
- Suspected anti-competitive behaviour relating to freelance and employed labour in the production, creation and/or broadcasting of television content, excluding sport
- Decision: Company Names Tribunal decision: Royce-Royce & Co Ltd
- Decision: Company Names Tribunal decision: Flexspace Tech Solution Limited
ACMD has written an updated harms assessment describing the use and harms of synthetic cathinones following a government commission.
Biographies of members of the Advisory Council on the Misuse of Drugs.
Four more experts have been appointed members to the Advisory Council on the Misuse of Drugs.
Occupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD).
ACMD has written an updated harms assessment describing the use and harms of synthetic cathinones following a government commission.
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
The government commissions the Advisory Council on the Misuse of Drugs (ACMD) to conduct an updated harms assessment of ketamine.
Occupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD).
Ten leading experts have joined the Advisory Council on the Misuse of Drugs (ACMD) to strengthen its vital work advising the government on drug harms.
Biographies of members of the Advisory Council on the Misuse of Drugs.
Biographies of members of the Advisory Council on the Misuse of Drugs.
Ten leading experts have joined the Advisory Council on the Misuse of Drugs (ACMD) to strengthen its vital work advising the government on drug harms.
A document developed by the Advisory Council on the Misuse of Drugs (ACMD) to outline the governing process for preparing evidence-based advice.
Overview of the Advisory Council on the Misuse of Drugs' (ACMD) work from January 2020 to December 2022.
Occupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD).
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
The Advisory Council on the Misuse of Drugs responds to the government on their proposal to amend the licensing regimen for industrial hemp.
Occupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD).
The Advisory Council on the Misuse of Drugs has provided an updated harms assessment of alkyl nitrites.
The Novel Psychoactive Substances Committee (NPSC) is seeking evidence for its review of the evidence of the misuse and harms of synthetic cathinones in the UK.
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
The Advisory Council on the Misuse of Drugs has provided an updated harms assessment of alkyl nitrites.
ACMD work programme 2024 letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD).
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
A review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update).
A review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update).
This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.
This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.
Government response to the third addendum to the Advisory Council on the Misuse of Drugs' report on 2-benzyl benzimidazole and piperidine benzimidazolone opioids.
Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.
Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.
Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.
ACMD work programme 2024 letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD).
Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.
The Advisory Council on the Misuse of Drugs (ACMD) seeks to gather insight into current government-led drug prevention policies and landscape across the UK.
Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.
The Advisory Council on the Misuse of Drugs call for evidence, collecting written evidence to better understand internet-facilitated drug markets (IFDMs).
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
Fifteen new synthetic opioids and 5 other drugs will be banned as Class A drugs as the government continues to act to prevent drug deaths.
The Advisory Council on the Misuse of Drugs call for evidence, collecting written evidence to better understand internet-facilitated drug markets (IFDMs).
Report from the Advisory Council on the Misuse of Drugs (ACMD) on consumer cannabidiol (CBD) products.
The government responds to a report by the Advisory Council on the Misuse of Drugs and commissions Part 2 of work on barriers to research.
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
Ministerial Departmental News
- PM's Office, 10 Downing Street
- Cabinet Office
- Department for Business, Innovation and Skills
- Department for Communities and Local Government
- Department for Culture, Media and Sport
- Department for Education
- Department for Environment, Food and Rural Affairs
- Department for International Development
- Department for Transport
- Department for Work and Pensions
- Department of Energy and Climate Change
- Department of Health
- Foreign and Commonwealth Office
- HM Treasury
- Home Office
- Ministry of Defence
- Ministry of Justice
- Northern Ireland Office
- Scotland Office
- Wales Office
- See all departments